MediciNova Achieves Target Enrollment for COMBAT-ALS Trial, Advances Development of MN-166 for ALS Treatment
Reuters
Sep 08
MediciNova Achieves Target Enrollment for COMBAT-ALS Trial, Advances Development of MN-166 for ALS Treatment
MediciNova, Inc., a biopharmaceutical company, announced the completion of target enrollment in its COMBAT-ALS Phase 2b/3 clinical trial for its lead compound MN-166 (ibudilast), which is under development for the treatment of Amyotrophic Lateral Sclerosis (ALS). The company highlighted that this milestone is significant for ALS research. The results of the trial will be presented in the future, as the trial is among the most advanced in the field. Additionally, MediciNova is conducting a large Expanded Access Program supported by a $22 million NIH grant and is nearing completion of patient enrollment in a Phase 2 clinical trial for hypertriglyceridemia and fatty liver disease due to Type 2 diabetes with its second asset, MN-001 (Tipelukast). The company also secured a Standby Equity Purchase Agreement for up to $30 million, providing flexibility to support its ongoing R&D and corporate initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524535-en) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.